| 1.29 -0.03 (-2.27%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.63 | 1-year : | 3.38 |
| Resists | First : | 2.25 | Second : | 2.9 |
| Pivot price | 2.01 |
|||
| Supports | First : | 1.22 | Second : | 1.01 |
| MAs | MA(5) : | 1.5 |
MA(20) : | 2.12 |
| MA(100) : | 2.49 |
MA(250) : | 5.54 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.9 |
D(3) : | 9.8  |
| RSI | RSI(14): 26.8 |
|||
| 52-week | High : | 20.65 | Low : | 1.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HEPA ] has closed above bottom band by 6.4%. Bollinger Bands are 48.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.35 - 1.36 | 1.36 - 1.36 |
| Low: | 1.25 - 1.26 | 1.26 - 1.27 |
| Close: | 1.27 - 1.29 | 1.29 - 1.3 |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Mon, 22 Apr 2024
Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday? - Hepion Pharma - Benzinga
Mon, 22 Apr 2024
Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today? - InvestorPlace
Fri, 19 Apr 2024
Hepion ends Phase 2 study for NASH drug due to cash restraints (NASDAQ:HEPA) - Seeking Alpha
Tue, 02 Apr 2024
Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a share - Earnings Preview - XM
Fri, 01 Mar 2024
What is the Market's View on Hepion Pharmaceuticals Inc (HEPA) Stock's Price and Volume Trends Friday? - InvestorsObserver
Fri, 16 Feb 2024
Hepion Pharmaceuticals Bolsters Capital with Equity Deals - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 17.2 (%) |
| Shares Short | 63 (K) |
| Shares Short P.Month | 70 (K) |
| EPS | -12.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -63.2 % |
| Return on Equity (ttm) | -118.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -0.11 |
| PEG Ratio | 0 |
| Price to Book value | 0.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|